Results 31 to 40 of about 2,001,669 (363)
Synergistic drug combinations from electronic health records and gene expression. [PDF]
, 2016 ObjectiveUsing electronic health records (EHRs) and biomolecular data, we sought to discover drug pairs with synergistic repurposing potential. EHRs provide real-world treatment and outcome patterns, while complementary biomolecular data, including ...
Chen, William +19 more
core +2 more sources
Choosing the safest acute combination therapy during prophylactic treatment. pharmacokinetic and pharmacodynamic considerations [PDF]
, 2015 Drugs used in the treatment of migraine have been recently reported to be highly associated with the occurrence of clinically significant drug-drug interactions (DDIs)
Lionetto, Luana, MARTELLETTI, Paolo
core +1 more source
Data-driven prediction of adverse drug reactions induced by drug-drug interactions
BMC Pharmacology and Toxicology, 2017 Background The expanded use of multiple drugs has increased the occurrence of adverse drug reactions (ADRs) induced by drug-drug interactions (DDIs). However, such reactions are typically not observed in clinical drug-development studies because most of ...
Ruifeng Liu +5 more
doaj +1 more source
Optimizing higher-order network topology for synchronization of coupled phase oscillators [PDF]
arXiv, 2021 Networks in nature have complex interactions among agents. One significant phenomenon induced by interactions is synchronization of coupled agents, and the interactive network topology can be tuned to optimize synchronization. The previous studies showed that the optimized conventional network with pairwise interactions favors a homogeneous degree ...
arxiv
A Review of Daclatasvir Drug–Drug Interactions [PDF]
Advances in Therapy, 2016 The treatment of hepatitis C virus (HCV) infection has been revolutionized in recent years by the development of direct-acting antiviral regimens that do not contain peginterferon (pegIFN) and/or ribavirin (RBV). While direct-acting antiviral-based regimens have been shown to be greatly superior to pegIFN/RBV-based regimens in terms of efficacy and ...
Shu-Pang Huang +7 more
openaire +2 more sources
Nature Communications, 2018 SAMHD1 is a critical restriction factor for HIV-1 and its antiviral activity is regulated by T592 phosphorylation. Here, Schott et al. show that the phosphatase PP2A-B55α dephosphorylates SAMHD1 during mitotic exit, rendering it antivirally active in G1 ...
Kerstin Schott +14 more
doaj +1 more source
Drug–Drug–Gene Interactions in Cardiovascular Medicine
Pharmacogenomics and Personalized Medicine, 2022 Innocent G Asiimwe, Munir Pirmohamed The Wolfson Centre for Personalized Medicine, MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool ...
Asiimwe IG, Pirmohamed M
doaj
Magnitude of Drug–Drug Interactions in Special Populations
Pharmaceutics, 2022 Drug–drug interactions (DDIs) are one of the most frequent causes of adverse drug reactions or loss of treatment efficacy. The risk of DDIs increases with polypharmacy and is therefore of particular concern in individuals likely to present comorbidities (
Sara Bettonte +2 more
doaj +1 more source
PharmaceuticalsClinical practice entails a translation of research that assists in the use of scientific data and therapeutic evidence for the benefit of the patient. This review critically summarizes the potential impact of cannabinoids in conjunction with other drugs
Maria G. Campos +6 more
doaj +1 more source
Insights into CYP2B6-mediated drug–drug interactions
Acta Pharmaceutica Sinica B, 2016 Mounting evidence demonstrates that CYP2B6 plays a much larger role in human drug metabolism than was previously believed. The discovery of multiple important substrates of CYP2B6 as well as polymorphic differences has sparked increasing interest in the ...
William D. Hedrich +2 more
doaj +1 more source